Long-Acting Beta-Agonists (LTBAs) Received a Black Box Warning from the U.S

question 7

Multiple Choice

Long-acting beta-agonists (LTBAs) received a Black Box Warning from the U.S. Food and Drug Administration due to the:

• A) Risk of life-threatening dermatological reactions
• B) Increased incidence of cardiac events when LTBAs are used
• C) Increased risk of asthma-related deaths when LTBAs are used
• D) Risk for life-threatening alterations in electrolytes